Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Pliant Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Pliant Therapeutics, Inc. (PLRX) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. (“Pliant” or “the Company”) (NASDAQ: PLRX). Investors who purchased Pliant securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Pliant has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On February 7, 2025, Pliant issued a press release “announc[ing] that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).” Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast’s path forward. On this news, Pliant’s stock price fell $4.72 per share, or 60.59%, to close at $3.07 per share on February 10, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Pliant securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
How Did Pliant Therapeutics, Inc. (PLRX) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”